CuraRN

NSG210 Hinkle Ch. 19: Management of Patients With Chest and Lower Respiratory Tract Disorders

Source: Hinkle & Cheever, Brunner & Suddarth’s Medical-Surgical Nursing 15e, Chapter 19, pp. 526-598 (textbooks/HINKLE_MS_CH19.pdf, also in textbooks/exam03/). Week 09 reading (lung cancer and chest tubes); on Exam 3. Numbering note: the syllabus lists “Ch. 20,” but Ch. 20 is chronic pulmonary disease (already covered for Exam 1, nsg210-hinkle-ch20-chronic-pulmonary-disease); lung cancer, thoracotomy, chest trauma, and chest drainage are in Ch. 19.

Learning Outcomes

  1. Identify patients at risk for atelectasis and nursing interventions for prevention and management.
  2. Compare pulmonary infections by cause, manifestations, management, complications, prevention.
  3. Identify nursing care for a patient with an endotracheal tube, mechanical ventilation, or tracheostomy.
  4. Relate ARDS management to its pathophysiology.
  5. Describe prevention of occupational lung disease.
  6. Discuss therapy and nursing management for lung cancer.
  7. Use the nursing process for pneumonia, mechanical ventilation, and thoracotomy.
  8. Describe complications of chest trauma.
  9. Explain principles of chest drainage and nursing responsibilities.

I. Atelectasis

II. Acute Tracheobronchitis

III. Pneumonia

A. Risk factors and prevention (Table 19-2)

B. Clinical manifestations

C. Diagnosis

D. Treatment

E. Nursing process for bacterial pneumonia

F. COVID-19 pneumonia (summary)

IV. Aspiration

V. Pulmonary Tuberculosis

Diagnosis

Treatment (Table 19-4)

Drug Key side effects Nursing
Isoniazid Peripheral neuritis, hepatitis Pyridoxine (B6) prevents neuritis; no alcohol; avoid tyramine foods (aged cheese, tuna, red wine, soy sauce) - flushing, headache, hypotension; monitor AST/ALT
Rifampin Hepatitis, orange-red body fluids Stains contact lenses (wear glasses); reduces effect of oral contraceptives (use backup), warfarin, digoxin, steroids, oral hypoglycemics, beta-blockers
Pyrazinamide Hyperuricemia, hepatotoxicity, arthralgias Monitor uric acid, liver enzymes
Ethambutol Optic neuritis Baseline and monthly visual acuity and red-green color vision

Nursing management

VI. Lung Abscess

VII. Sarcoidosis

VIII. Pleural Disorders

A. Pleurisy

B. Pleural effusion

C. Empyema

IX. Acute Respiratory Failure

X. Endotracheal Intubation and Tracheostomy

A. Endotracheal (ET) tube

B. Tracheostomy

XI. Mechanical Ventilation

A. Indications (Chart 19-14)

B. Ventilator types and modes

C. Initial settings and monitoring

D. Troubleshooting (Table 19-5)

E. VAP bundle (Chart 19-6)

F. Nursing care

G. Weaning (Chart 19-19)

XII. Acute Respiratory Distress Syndrome (ARDS)

XIII. Pulmonary Vascular Disorders

XIV. Occupational Lung Disease (Pneumoconioses)

XV. Lung Cancer (Bronchogenic Carcinoma)

A. Classification

B. Clinical manifestations

C. Diagnosis

D. Treatment

E. Nursing management

XVI. Thoracic Surgery (Chart 19-22)

A. Preoperative teaching

B. Postoperative care (Chart 19-23)

C. Home teaching (Chart 19-25)

XVII. Mediastinal Tumors

XVIII. Chest Trauma

A. Sternal and rib fractures

B. Flail chest

C. Pulmonary contusion

D. Pneumothorax

E. Cardiac tamponade

F. Subcutaneous emphysema

XIX. Chest Drainage Systems (Table 19-8)

A. Traditional (wet) water-seal system - three chambers

B. Dry suction water-seal system

C. Dry suction with one-way valve

D. Key nursing safety points

High-Yield Numbers

Priority Nursing Actions and Red Flags

Medications

Drug Class Indication Nursing considerations
Ceftriaxone, azithromycin, levofloxacin Antibiotics CAP Cultures first; switch IV to PO when stable
Vancomycin, linezolid Antibiotics MRSA Contact precautions; vancomycin troughs, kidney function
Piperacillin-tazobactam, cefepime, meropenem Antipseudomonal antibiotics HAP, VAP Reassess at 72 hours
Trimethoprim-sulfamethoxazole Sulfonamide antibiotic Pneumocystis (PCP) Rash, hyperkalemia; fluids
Oseltamivir Neuraminidase inhibitor Influenza Start within 48 hours of symptoms
Clindamycin Antibiotic Aspiration pneumonia, lung abscess C. difficile risk
PCV13, PPSV23 Pneumococcal vaccines Prevention 65+; PCV13 first, PPSV23 at least 1 year later
Isoniazid Anti-TB Active and latent TB Pyridoxine; no alcohol; avoid tyramine; liver enzymes
Rifampin Anti-TB Active TB Orange body fluids, stains contacts; reduces oral contraceptive effect
Pyrazinamide Anti-TB Active TB Uric acid, liver enzymes
Ethambutol Anti-TB Active TB Visual acuity and color vision
Talc Sclerosing agent Pleurodesis for malignant effusion Clamp 60-90 minutes; reposition; pain control
Acetylcysteine Mucolytic Thick secretions Bronchospasm, nausea
Propofol, dexmedetomidine, midazolam Sedatives Ventilated patients Daily sedation vacation; dexmedetomidine during weaning
Vecuronium, rocuronium Neuromuscular blockers ARDS ventilation Always with sedation and analgesia; train-of-four; eye care
Epoprostenol Prostanoid Pulmonary hypertension Continuous IV via central line; never interrupt (half-life under 3 minutes)
Sildenafil, bosentan PDE-5 inhibitor, endothelin antagonist Pulmonary hypertension Bosentan: monitor liver function
Pembrolizumab, nivolumab, durvalumab Checkpoint inhibitors NSCLC Immune-related effects: rash, diarrhea, pneumonitis
Remdesivir Antiviral Severe COVID-19 Per current guidelines